Abstract
The hemostatic cascade is initiated by the transmembrane coagulation protein – tissue factor (TF) and eventuates in fibrin formation. Heparanase protein was demonstrated to directly enhance TF activity resulting in increased activation of the coagulation system. In addition, heparanase was found to increase hemostatic system activation via two other mechanisms: up-regulating TF expression in endothelial cells and releasing the protein tissue factor pathway inhibitor (TFPI) from the cell surface. Peptides derived from TFPI-2, a protein similar to TFPI, were shown to inhibit the TF/heparanase complex as well as attenuate sepsis and tumor growth. Increased heparanase procoagulant activity was observed in several clinical settings, including women using oral contraceptives, women at delivery, patients following orthopedic surgery and patients with diabetic foot, shift work female nurses, patients with lung cancer, retinal vein thrombosis and prosthetic heart valve thrombosis. Remarkably, the heparanase profile was significantly different across the tested groups. Inhibition of TF / heparanase interaction may represent a new target for attenuating coagulation, cancer and inflammation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Camerer, E., Kolsto, A. B., & Prydz, H. (1996). Cell biology of tissue factor, the principal initiator of blood coagulation. Thrombosis Research, 81(1), 1–41.
Corseaux, D., Meurice, T., Six, I., et al. (2000). Basic fibroblast growth factor increases tissue factor expression in circulating monocytes and in vascular wall. Circulation, 101(16), 2000–2006.
Ernofsson, M., & Siegbahn, A. (1996). Platelet-derived growth factor-BB and monocyte chemotactic protein-1 induce human peripheral blood monocytes to express tissue factor. Thrombosis Research, 83(4), 307–320.
Clauss, M., Murray, J. C., Vianna, M., et al. (1990). A polypeptide factor produced by fibrosarcoma cells that induces endothelial tissue factor and enhances the procoagulant response to tumor necrosis factor/cachectin. The Journal of Biological Chemistry, 265(12), 7078–7083.
Collins, P. W., Noble, K. E., Reittie, J. R., et al. (1995). Induction of tissue factor expression in human monocyte/endothelium cocultures. British Journal of Haematology, 91(4), 963–970.
Yan, S. F., Pinsky, D. J., & Stern, D. M. (2000). A pathway leading to hypoxia-induced vascular fibrin deposition. Seminars in Thrombosis and Hemostasis, 26(5), 479–483.
Drake, T. A., & Pang, M. (1989). Effects of interleukin-1, lipopolysaccharide, and streptococci on procoagulant activity of cultured human cardiac valve endothelial and stromal cells. Infection and Immunity, 57(2), 507–512.
Zhang, Y., Deng, Y., Luther, T., et al. (1994). Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. The Journal of Clinical Investigation, 94(3), 1320–1327.
Nakasaki, T., Wada, H., Shigemori, C., et al. (2002). Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer. American Journal of Hematology, 69(4), 247–254.
Contrino, J., Hair, G., Kreutzer, D. L., & Rickles, F. R. (1996). In situ detection of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast disease. Nature Medicine, 2(2), 209–215.
Koomagi, R., & Volm, M. (1998). Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: Correlation between tissue factor and angiogenesis. International Journal of Cancer, 79(1), 19–22.
Carmeliet, P., Mackman, N., Moons, L., et al. (1996). Role of tissue factor in embryonic blood vessel development. Nature, 383(6595), 73–75.
Nadir, Y., Brenner, B., Zetser, A., et al. (2006). Heparanase induces tissue factor expression in vascular endothelial and cancer cells. Journal of Thrombosis and Haemostasis, 4(11), 2443–2451.
Lwaleed, B. A., & Bass, P. S. (2006). Tissue factor pathway inhibitor: Structure, biology and involvement in disease. The Journal of Pathology, 208(3), 327–339.
Kamikura, Y., Wada, H., Yamada, A., et al. (1997). Increased tissue factor pathway inhibitor in patients with acute myocardial infarction. American Journal of Hematology, 55(4), 183–187.
Leurs, P. B., Stolk, R. P., Hamulyak, K., et al. (2002). Tissue factor pathway inhibitor and other endothelium-dependent hemostatic factors in elderly individuals with normal or impaired glucose tolerance and type 2 diabetes. Diabetes Care, 25(8), 1340–1345.
Yamamuro, M., Wada, H., Kumeda, K., et al. (1998). Changes in plasma tissue factor pathway inhibitor levels during the clinical course of disseminated intravascular coagulation. Blood Coagulation & Fibrinolysis, 9(6), 491–497.
Iversen, N., Lindahl, A. K., & Abildgaard, U. (1998). Elevated TFPI in malignant disease: Relation to cancer type and hypercoagulation. British Journal of Haematology, 102(4), 889–895.
Iversen, N., Lindahl, A. K., & Abildgaard, U. (2002). Elevated plasma levels of the factor Xa-TFPI complex in cancer patients. Thrombosis Research, 105(1), 33–36.
Al-Mugeiren, M. M., Abdel Gader, A. G., Al-Rasheed, S. A., & Al-Salloum, A. A. (2006). Tissue factor pathway inhibitor in childhood nephrotic syndrome. Pediatric Nephrology, 21(6), 771–777.
Nadir, Y., Brenner, B., Gingis-Velitski, S., et al. (2008). Heparanase induces tissue factor pathway inhibitor expression and extracellular accumulation in endothelial and tumor cells. Thrombosis and Haemostasis, 99(1), 133–141.
Nadir, Y., Brenner, B., Fux, L., et al. (2010). Heparanase enhances the generation of activated factor X in the presence of tissue factor and activated factor VII. Haematologica, 95(11), 1927–1934.
Baker, A. B., Gibson, W. J., Kolachalama, V. B., et al. (2012). Heparanase regulates thrombosis in vascular injury and stent-induced flow disturbance. Journal of the American College of Cardiology, 59(17), 1551–1560.
Sprecher, C. A., Kisiel, W., Mathewes, S., & Foster, D. C. (1994). Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor. Proceedings of the National Academy of Sciences of the United States of America, 91(8), 3353–3357.
Parish, C. R., Freeman, C., & Hulett, M. D. (2001). Heparanase: A key enzyme involved in cell invasion. Biochimica et Biophysica Acta, 1471(3), M99–M108.
Vlodavsky, I., & Friedmann, Y. (2001). Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. The Journal of Clinical Investigation, 108(3), 341–347.
Udagawa, K., Yasumitsu, H., Esaki, M., et al. (2002). Subcellular localization of PP5/TFPI-2 in human placenta: A possible role of PP5/TFPI-2 as an anti-coagulant on the surface of syncytiotrophoblasts. Placenta, 23(2–3), 145–153.
Tatour, M., Shapira, M., Axelman, E., et al. (2017). Thrombin is a selective inducer of heparanase release from platelets and granulocytes via protease-activated receptor-1. Thrombosis and Haemostasis, 117(7), 1391–1401.
Cui, H., Tan, Y. X., Osterholm, C., et al. (2016). Heparanase expression upregulates platelet adhesion activity and thrombogenicity. Oncotarget, 7(26), 39486–39496.
Tan, Y. X., Cui, H., Wan, L. M., et al. (2018). Overexpression of heparanase in mice promoted megakaryopoiesis. Glycobiology, 28(5), 269–275.
Ward, A. C., Touw, I., & Yoshimura, A. (2000). The Jak-stat pathway in normal and perturbed hematopoiesis. Blood, 95(1), 19–29.
Parganas, E., Wang, D., Stravopodis, D., et al. (1998). Jak2 is essential for signaling through a variety of cytokine receptors. Cell, 93(3), 385–395.
Silvennoinen, O., Witthuhn, B. A., Quelle, F. W., et al. (1993). Structure of the murine Jak2 protein-tyrosine kinase and its role in interleukin 3 signal transduction. Proceedings of the National Academy of Sciences of the United States of America, 90(18), 8429–8433.
Kogan, I., Chap, D., Hoffman, R., et al. (2016). JAK-2 V617F mutation increases heparanase procoagulant activity. Thrombosis and Haemostasis, 115(1), 73–80.
Axelman, E., Henig, I., Crispel, Y., et al. (2014). Novel peptides that inhibit heparanase activation of the coagulation system. Thrombosis and Haemostasis, 112(3), 466–477.
Crispel, Y., Ghanem, S., Attias, J., et al. (2017). Involvement of the heparanase procoagulant domain in bleeding and wound healing. Journal of Thrombosis and Haemostasis, 15(7), 1463–1472.
Nadir, Y., Kenig, Y., Drugan, A., Shafat, I., & Brenner, B. (2011). An assay to evaluate heparanase procoagulant activity. Thrombosis Research, 128(4), e3–e8.
Shafat, I., Zcharia, E., Nisman, B., et al. (2006). An ELISA method for the detection and quantification of human heparanase. Biochemical and Biophysical Research Communications, 341(4), 958–963.
Matan, M., Axelman, E., Brenner, B., & Nadir, Y.Heparanase procoagulant activity is elevated in women using oral contraceptives. Human Reproduction, 28(9), 2372–2380.
Peled, E., Rovitsky, A., Axelman, E., et al. (2012). Increased heparanase level and procoagulant activity in orthopedic surgery patients receiving prophylactic dose of enoxaparin. Thrombosis Research, 130(1), 129–134.
Matan, M., King, D., Peled, E., et al. (2017). Heparanase level and procoagulant activity are reduced in severe sepsis. European Journal of Haematology.
Nadir, Y., Saharov, G., Hoffman, R., et al. (2015). Heparanase procoagulant activity, factor Xa, and plasminogen activator inhibitor 1 are increased in shift work female nurses. Annals of Hematology, 94(7), 1213–1219.
Peled, E., Melamed, E., Portal, T. B., et al. (2016). Heparanase procoagulant activity as a predictor of wound necrosis following diabetic foot amputation. Thrombosis Research, 139, 148–153.
Lanir, N., Aharon, A., & Brenner, B. (2003). Procoagulant and anticoagulant mechanisms in human placenta. Seminars in Thrombosis and Hemostasis, 29(2), 175–184.
Haimov-Kochman, R., Friedmann, Y., Prus, D., et al. (2002). Localization of heparanase in normal and pathological human placenta. Molecular Human Reproduction, 8(6), 566–573.
Goshen, R., Hochberg, A. A., Korner, G., et al. (1996). Purification and characterization of placental heparanase and its expression by cultured cytotrophoblasts. Molecular Human Reproduction, 2(9), 679–684.
Nadir, Y., Henig, I., Naroditzky, I., et al. (2010). Involvement of Heparanase in early pregnancy losses. Thrombosis Research, 125(5), e251–e257.
Nadir, Y., Kenig, Y., Drugan, A., Zcharia, E., & Brenner, B. (2010). Involvement of heparanase in vaginal and cesarean section deliveries. Thrombosis Research, 126(6), e444–e450.
McCarthy C, Cotter FE, McElwaine S, et al. 2007 Altered gene expression patterns in intrauterine growth restriction: Potential role of hypoxia. American Journal of Obstetrics and Gynecology,196(1):70 e71–76.
Fetalvero, K. M., Zhang, P., Shyu, M., et al. (2008). Prostacyclin primes pregnant human myometrium for an enhanced contractile response in parturition. The Journal of Clinical Investigation, 118(12), 3966–3979.
Salem, H. T., Westergaard, J. G., Hindersson, P., et al. (1982). Maternal serum levels of placental protein 5 in complications of late pregnancy. Obstetrics and Gynecology, 59(4), 467–471.
Deitcher, S. R., & Gomes, M. P. (2004). The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: A systematic review. Cancer, 101(3), 439–449.
Rosing, J., Middeldorp, S., Curvers, J., et al. (1999). Low-dose oral contraceptives and acquired resistance to activated protein C: A randomised cross-over study. Lancet, 354(9195), 2036–2040.
Elkin, M., Cohen, I., Zcharia, E., et al. (2003). Regulation of heparanase gene expression by estrogen in breast cancer. Cancer Research, 63(24), 8821–8826.
Matan, M., Axelman, E., Brenner, B., & Nadir, Y. (2013). Heparanase procoagulant activity is elevated in women using oral contraceptives. Human Reproduction, 28(9), 2372–2380.
Nadir, Y., Sarig, G., Axelman, E., et al. (2014). Heparanase procoagulant activity is elevated and predicts survival in non-small cell lung cancer patients. Thrombosis Research, 134(3), 639–642.
Crispel, Y., Axelman, E., Tatour, M., et al. (2016). Peptides inhibiting heparanase procoagulant activity significantly reduce tumour growth and vascularisation in a mouse model. Thrombosis and Haemostasis, 116(4), 669–678.
Hu, Y., Atik, A., Yu, H., et al. (2017). Serum heparanase concentration and heparanase activity in patients with retinal vein occlusion. Acta Ophthalmologica, 95(1), e62–e66.
Bayam, E., Kalcik, M., Gurbuz, A. S., et al. (2018). The relationship between heparanase levels, thrombus burden and thromboembolism in patients receiving unfractionated heparin treatment for prosthetic valve thrombosis. Thrombosis Research, 171, 103–110.
Campisi, J. (2005). Aging, tumor suppression and cancer: High wire-act! Mechanisms of Ageing and Development, 126(1), 51–58.
Bochenek, M. L., Bauer, T., Gogiraju, R., et al. (2018). The endothelial tumor suppressor p53 is essential for venous thrombus formation in aged mice. Blood Adv, 2(11), 1300–1314.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Nadir, Y. (2020). Heparanase in the Coagulation System. In: Vlodavsky, I., Sanderson, R., Ilan, N. (eds) Heparanase. Advances in Experimental Medicine and Biology, vol 1221. Springer, Cham. https://doi.org/10.1007/978-3-030-34521-1_33
Download citation
DOI: https://doi.org/10.1007/978-3-030-34521-1_33
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-34520-4
Online ISBN: 978-3-030-34521-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)